Tirzepatide (LY3298176) is the first-in-class dual incretin receptor agonist, combining GLP-1 and GIP activity in a single unimolecular peptide, representing a significant advancement over Semaglutide which is GLP-1 only. It is engineered with a C20 fatty diacid moiety to extend half-life to ∼5 days for once-weekly research protocols. This compound is designed for Type 2 Diabetes models with insulin resistance and poor glycemic control, obesity research with metabolic syndrome, studies requiring both glucose-dependent insulin secretion and superior appetite suppression, and protocols where GLP-1 tolerability is improved by GIP co-activation.
Tirzepatide achieves dual control through two distinct receptor pathways that amplify each other. In the Pancreas Mechanism, Tirzepatide activates GLP-1R on pancreatic β-cells → ↑cAMP → PKA pathway → stimulates glucose-dependent insulin release from beta-cells, improves insulin synthesis & secretion, and helps lower blood glucose. Simultaneously, on α-cells it suppresses glucagon release, reduces hepatic glucose output, and improves overall glycemic control. In the GIPR Activation, Tirzepatide enhances insulin release via GIPR on β-cells, supporting metabolism. In the Brain & Appetite Mechanism, it acts on the Hypothalamus Appetite & Satiety Center → reduces hunger signaling via POMC neurons → promotes fullness, and on Area Postrema / Hindbrain, GIPR activation reduces nausea & improves tolerance to GLP-1 effects. This leads to Appetite Suppression (acts on hypothalamic feeding centers → lower food intake & increased satiety), Slows Gastric Emptying (food stays in stomach longer → prolonged fullness), and Reward/Craving Reduction (modulates mesolimbic reward pathways → reduced cravings for high-calorie foods). The integrated outcome is lower blood glucose via enhanced insulin + reduced glucagon, average 15-22.5% body weight reduction, metabolic improvement in insulin sensitivity and lipid profile, and better tolerance versus GLP-1 mono-agonists.
Our Tirzepatide lineup is supplied as high-purity lyophilized powder (>99% HPLC) with COA. For dose-escalation and maintenance research, we offer Tirzepatide 5mg (starter), Tirzepatide 10mg (standard - most requested), Tirzepatide 15mg (intermediate), Tirzepatide 20mg / 30mg (high-dose), and Tirzepatide 60mg (value bulk size). Each vial is stable 24 months at -20°C. Compared to Semaglutide 5mg/10mg, Tirzepatide shows greater weight loss (up to 22.5% vs ∼15%) and superior HbA1c reduction (∼2.3% vs ∼1.8%) in research due to dual incretin action. Ideal for stacking studies with B12 (energy), BPC-157 (gut), and AOD 9604 (fat metabolism) for comprehensive metabolic protocols. For Research Use Only, not for human consumption.